Host Immune-Metabolic Adaptations Upon Mycobacterial Infections and Associated Co-Morbidities

Alba Llibre1*, Martin Dedicoat2, Julie G. Burel3, Caroline Demangel4†, Matthew K. O’Shea2,5† and Claudio Mauro1*†

1 Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 2 Department of Infectious Diseases, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 3 Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, United States, 4 Immunobiology of Infection Unit, Institut Pasteur, INSERM U1224, Paris, France, 5 Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom

Mycobacterial diseases are a major public health challenge. Their causative agents include, in order of impact, members of the Mycobacterium tuberculosis complex (causing tuberculosis), Mycobacterium leprae (causing leprosy), and non-tuberculous mycobacterial pathogens including Mycobacterium ulcerans. Macrophages are mycobacterial targets and they play an essential role in the host immune response to mycobacteria. This review aims to provide a comprehensive understanding of the immune-metabolic adaptations of the macrophage to mycobacterial infections. This metabolic rewiring involves changes in glycolysis and oxidative metabolism, as well as in the use of fatty acids and that of metals such as iron, zinc and copper. The macrophage metabolic adaptations result in changes in intracellular metabolites, which can post-translationally modify proteins including histones, with potential for shaping the epigenetic landscape. This review will also cover how critical tuberculosis co-morbidities such as smoking, diabetes and HIV infection shape host metabolic responses and impact disease outcome. Finally, we will explore how the immune-metabolic knowledge gained in the last decades can be harnessed towards the design of novel diagnostic and therapeutic tools, as well as vaccines.

Keywords: mycobacteria, macrophage, immunometabolism, host-directed therapies, tuberculosis

INTRODUCTION

Mycobacteria have been a major cause of human disease for millennia, with the effects of Mycobacterium tuberculosis (M.tb) seen in the skeletons of mummified human remains from over 4000 years ago (1). The main mycobacteria of public health importance today are members of the mycobacterium tuberculosis complex (which includes M.tb, M.bovis, M.africanum, M.microti, M.pinnepedi, M.caprae), which cause tuberculosis (TB), Mycobacterium leprae (M.leprae) the cause...
of leprosy, and nontuberculous mycobacteria (NTM) leading to a wide variety of clinical presentations. NTM include *Mycobacterium ulcerans* (*M.ulcerans*), the cause of Buruli ulcer (BU).

Around 2 billion people worldwide are infected with *M.tb*. Approximately 10 million people fall ill with TB each year and there are around 1.5 million deaths (2). Great progress has been made with TB control over the past decade, but these gains have been undermined to some extent by the ongoing Covid-19 pandemic, especially in less well-resourced settings (3). Current treatment for drug sensitive TB is a minimum of 6 months and considerably longer for drug resistant disease. Shorter more effective treatments are needed, and host-directed therapies (HDT) arise as a promising strategy.

Leprosy caused by chronic infection with *M.leprae* is predominantly a disease of the skin and peripheral nerves. It is curable with a prolonged course of antibiotics. The incidence of leprosy has declined over the past century, but the rate of decline is currently sluggish. A large proportion of endemic countries (118/161) reported new cases in 2019 (202,256 or 26 per million population) (4). Although antibiotics can still cure the disease, permanent changes to nerves can occur leading to lifelong disabilities. There is still a great amount of stigma around the diagnosis of leprosy which can delay detection and effective treatment. Also, weak health systems can make early detection and treatment difficult. Current therapies although effective are prolonged and commonly associated with adverse effects (5).

Both TB and leprosy present a spectrum of clinical manifestations. TB can be described as a dynamic continuum from asymptomatic *M.tb* infection to active infectious disease, including latent infection as well as incipient, subclinical and active TB disease (6, 7). Leprosy also comprises ample clinical variability. The two extremes of the spectrum are tuberculoid and lepromatous forms of the disease, the first being paucibacillary and mild, while the latter is multibacillary and presents increased disease severity (8, 9).

There are over 200 species of NTM identified to date (10), of which the vast majority (over 95%) have not been associated with human disease. NTM are predominantly environmental organisms of low pathogenicity to humans that only cause disease in specific circumstances. An exception is *M.ulcerans*, which causes chronic skin ulcers in immunocompetent individuals, through production of a diffusible cytotoxin called mycolactone (11). BU is, after TB and leprosy, the third most common mycobacterial disease worldwide and together with leprosy one of the 20 Neglected Tropical Diseases prioritized by the WHO (12). West African countries are the worst impacted by BU, with prevalence rates reaching 26.9 cases per 10,000 in Benin. Other NTMs primarily affect immunocompromised people. Recently, NTM infections have been associated with health care procedures with infections due to *M.chimaerae* occurring after cardiac surgery (13) and infections with rapid growing NTM’s such as *M.abscessus* being associated with cosmetic surgery procedures (14). *M.abscessus* is also associated with progressive lung infection in patients with cystic fibrosis (15). Treatment of NTM infections is complex requiring multiple prolonged antibiotics which may not be effective or well tolerated. Overall, novel treatments for mycobacterial diseases are needed. HTDs are a promising approach but we need a greater understanding of how the host responds to infection.

**MACROPHAGES AS TARGETS OF MYCOBACTERIAL INFECTION**

Macrophages not only play an essential role in the host immune response to mycobacteria, but they also are mycobacterial targets. They fulfil a variety of essential functions in homeostasis and disease, including phagocytosis, uptake and killing of pathogens, tissue repair and inflammation resolution (16, 17). Mirroring their wide range of functions, macrophages constitute a highly diverse and heterogeneous population (18, 19). Traditionally, they have been classified into M1, i.e. classically-activated (LPS + IFNγ) and pro-inflammatory, and M2, i.e. alternatively-activated (IL-4) and anti-inflammatory. While the oversimplified M1/M2 dichotomy has been a useful tool when studying macrophage diversity, most macrophages exist as a spectrum and contain features of both (20, 21). Additionally, it is increasingly recognised that specific environmental cues can promote certain macrophage phenotypes and functions, demonstrating their plasticity. Metabolically, M1-like macrophages are predominantly glycolytic and present a broken TCA cycle (22). Their pentose phosphate pathway as well as fatty acid synthesis are highly active, ensuring availability of biosynthetic precursors. In contrast, M2-like macrophages mainly rely on oxidative metabolism, present an intact TCA cycle and fatty acid oxidation is upregulated. This review will explore macrophage metabolic diversity and flexibility and how these metabolic changes can drive specific phenotypes and functions, focusing on their relevance in the context of mycobacterial pathogenesis.

*M.tb* infection occurs when aerosols containing the bacilli are inhaled by a susceptible host. When *M.tb* reaches the lung, alveolar macrophages (AM), the first cellular target (23), are infected. Infected AMs can migrate to the lung interstitium, facilitating infection of other cell types, including newly-recruited monocyte-derived macrophages and neutrophils. Although abundant evidence points towards *M.leprae* being transmitted through the respiratory route (24, 25), the precise mechanisms for *M.leprae* spread remain to be fully elucidated (26). *M.leprae* primary cell targets are macrophages and Schwann cells, the latter contributing to build the myelin sheath that covers nerve fibres. Following introduction into the skin, *M.ulcerans* bacilli are phagocytosed by macrophages and multiply intracellularly until bacterial production of mycolactone causes host cell apoptosis (11, 27). Therefore, macrophages are a clear target for mycobacterial pathogens which have evolved successful strategies to survive and replicate within them (28), including metabolic manipulation.

In the context of mycobacterial disease, macrophages play an essential role in driving innate and adaptive immune responses...
and inflammation, while mediating both tissue destruction and repair (29). Two major macrophage populations cohabit in the lung: AMs and interstitial macrophages (IMs). They are distinct at the ontogenic, phenotypic, metabolic and functional levels (30). AMs display an M2-like phenotype (31) with predominant oxidative metabolism (30, 32), similar to IL-4 treated hMDM (33). In contrast, IMs are mainly derived from recruited monocytes (34, 35), and this has been particularly shown in the context of M.tb infection (30, 36). IMs are M1-like and operate at high levels of glycolysis (30). Other types of macrophages relevant in the context of mycobacterial infection include epithelioid cells, multinucleate giant cells (MGCs) and foamy, lipid-rich macrophages (37). MGCs are the result of macrophage fusion within the granuloma, organised cellular aggregates hallmark of TB and leprosy (38).

In leprosy, skin lesions from the milder, tuberculoid forms of the disease have been shown to have an M1-like macrophage predominant population, whereas in more severe skin lesions of multibacillary patients the balance shifts towards M2-like macrophages (39).

BU manifests as chronic ulcerative skin lesions with a distinctive lack of pain and inflammation, which if untreated enlarge over time (40). Tissue necrosis, local analgesia and defective inflammation are all attributed to bacterial production of mycolactone, a diffusible macrolide targeting the entry point of the secretory pathway in eukaryotic cells: the Sec61 translocon (11, 41, 42). By inhibiting Sec61, mycolactone prevents host cell’s production of secreted proteins, and most of its transmembrane proteins, leading to their cytosolic degradation by the proteasome (43–45). In the skin regions surrounding bacterial foci, complete and sustained inhibition of Sec61 in host cells triggers endoplasmic reticulum (ER) stress responses culminating in apoptosis (46). In immune cells recruited to the site of infection, including macrophages, exposure to non-cytotoxic concentrations of mycolactone prevents the production of cytokines, chemokines and the transduction of receptor-mediated signals, thereby the generation of protective immune responses (41). How M.tb, M.leprae and M.ulcerans impact the metabolic reprogramming of immune cells is explored in the following section, and is summarised in Table 1.

### IMMUNE-METABOLIC ADAPTATIONS OF THE MACROPHAGE TO MYCOBACTERIAL INFECTION

This section provides an overview of the current knowledge regarding the effects of M.tb, M.leprae and M.ulcerans on host macrophage glycolysis, oxidative and lipid metabolism (Figure 1).

#### Glycolysis Versus Oxidative Metabolism: Shaping Macrophage Polarisation

Activation of Toll-like receptors (TLRs) by mycobacterial components induces dynamic and coordinated changes in the energy metabolism of host macrophages similar to those occurring during macrophagic differentiation into the M1-like phenotype. They include a switch towards glycolysis, a disruption of the TCA cycle leading to the accumulation of succinate, and an impaired oxidative phosphorylation. Such alterations are promoted by the Hypoxia-Inducible Factor (HIF)-1α, an oxygen sensor and key glycolysis regulator that is activated by the TCA cycle intermediate succinate and mediates the production of Interleukin (IL)-1β (56). Induction of aerobic glycolysis and HIF-1α are beneficial for both innate and IFNγ-dependent control of intracellular M.tb infection by host macrophages (47, 57, 58). Importantly, in contrast to killed M.tb and the vaccine strain Bacille Calmette-Guérin (BCG), live M.tb was recently shown to specifically prevent the glycolytic switch in infected macrophages, pointing towards M.tb having evolved specific strategies to modulate host cell metabolism to its own benefit (48–50). Thus, there is an arms race to control macrophage metabolism as it is essential in determining infection outcome, and this topic has been extensively covered in recent excellent reviews (59–61). Validating this idea, it was shown in a mouse model of M.tb infection that ontologically and metabolically distinct lung

---

**TABLE 1 | M1-like vs M2-like macrophages in mycobacterial infection.**

|               | M1-like                                      | M2-like                                      |
|---------------|----------------------------------------------|----------------------------------------------|
| Baseline      | Predominantly glycolytic                     | Mainly reliant on oxidative metabolism       |
|               | Pro-inflammatory                             | Anti-inflammatory                            |
|               | Microbicidal                                 | Tissue repair                                |
|               | Key markers: CD86, INOS, ROS                 | Key markers: CD206, CD163, Arg               |
| M.tb          | Intersitial macrophages                      | Alveolar macrophages                         |
|               | Glycolysis needed for M.tb control (47)      | More permissive to M.tb growth (50)          |
|               | M.tb restricts glycolysis (68–69)            |                                             |
| M.leprae      | Predominant tuberculoid, lesions (39, 51)    | Predominant in severe lesions (39, 51)       |
|               | Blocks M1 polarization in infected monocytes (52) | Favor bacterial persistence (53)            |
|               |                                              | Infections promote M2 phenotype in hMDMs (54, 55) |
|               |                                              | Promotes Treg phenotype (54, 55)             |

Summary of the key distinctive factors between the M1-like and M2-like macrophage populations. Each population plays a different role in the context of M.tb and M.leprae infection, and have specific capabilities to combat infection, resulting in differential outcome.
macrophage populations (AMs and IMs) have differential capacities to control bacterial burden (30). Specifically, IMs which are predominantly monocyte-derived and glycolytic, present an increased ability to control \textit{M. tb} growth compared to AMs, a subset of embryonic origin committed to fatty acid oxidation. Although these findings require further validation in humans, a recent single cell RNA-seq study demonstrated that the majority of lung macrophage populations are conserved between mouse and human (62).

Reprogramming of energy metabolism in \textit{M. tb}-infected macrophages is also associated with increased levels of NADPH oxidase and inducible nitric oxide synthase (iNOS), promoting the production of reactive oxygen species (ROS) including nitric oxide (NO) with antimycobacterial activity (63, 64). In addition to yielding succinate, disruption of the TCA cycle upon \textit{M. tb} infection promotes the generation of itaconate from cis-aconitate byaconitate decarboxylase, also known as immune-responsive-gene 1 (IRG1). Although itaconate suppresses the production of inflammatory cytokines and ROS by infected macrophages (65, 66), it directly inhibits \textit{M. tb} enzymes isocitrate lyases Icl1/2, which are required for bacterial virulence and growth in vivo (67). IRG1 expression was shown to potentiate macrophage capacity to control intracellular \textit{M. tb} (68) and prevent immunopathology in a mouse model of \textit{M. tb} infection (69), demonstrating the key importance of this metabolic pathway in host defence against \textit{M. tb}.

Studies in Schwann cells suggested that infection with \textit{M. leprae} may also triggers major metabolic reprogramming in infected macrophages. Following infection by \textit{M. leprae}, Schwann cells increase the expression of insulin-like growth factor (IGF), upregulating glucose transporter 1 (GLUT-1) and glucose uptake by Akt signalling (70). Glucose is redirected from glycolysis to the pentose phosphate pathway through the activation of G6PD, increasing the carbon flux to lipid biosynthesis, while both mitochondrial activity and lactate production are reduced (71, 72). Since \textit{M. leprae} infection success depends on the pentose phosphate pathway, which generates reducing power for glutathione antioxidant system, it was proposed that \textit{M. leprae} subverts host cell glucose metabolism to facilitate glutathione regeneration and thereby free-radical control (71).

In vitro experiments demonstrated that M1-like macrophages acquire M2-like phenotypes in the presence of \textit{M. leprae} and apoptotic cells (which occur in skin lesions), contributing to mycobacterial persistence (52). Exposure of human CD14+ monocytes to \textit{M. leprae} (MOI 5:1) inhibited M1 polarization, decreasing the carbon flux to lipid biosynthesis, while both mitochondrial activity and lactate production are reduced (71, 72). Since \textit{M. leprae} infection success depends on the pentose phosphate pathway, which generates reducing power for glutathione antioxidant system, it was proposed that \textit{M. leprae} subverts host cell glucose metabolism to facilitate glutathione regeneration and thereby free-radical control (71).

In vitro experiments demonstrated that M1-like macrophages acquire M2-like phenotypes in the presence of \textit{M. leprae} and apoptotic cells (which occur in skin lesions), contributing to mycobacterial persistence (52). Exposure of human CD14+ monocytes to \textit{M. leprae} (MOI 5:1) inhibited M1 polarization, decreasing the carbon flux to lipid biosynthesis, while both mitochondrial activity and lactate production are reduced (71, 72). Since \textit{M. leprae} infection success depends on the pentose phosphate pathway, which generates reducing power for glutathione antioxidant system, it was proposed that \textit{M. leprae} subverts host cell glucose metabolism to facilitate glutathione regeneration and thereby free-radical control (71).

In vitro experiments demonstrated that M1-like macrophages acquire M2-like phenotypes in the presence of \textit{M. leprae} and apoptotic cells (which occur in skin lesions), contributing to mycobacterial persistence (52). Exposure of human CD14+ monocytes to \textit{M. leprae} (MOI 5:1) inhibited M1 polarization, decreasing the carbon flux to lipid biosynthesis, while both mitochondrial activity and lactate production are reduced (71, 72). Since \textit{M. leprae} infection success depends on the pentose phosphate pathway, which generates reducing power for glutathione antioxidant system, it was proposed that \textit{M. leprae} subverts host cell glucose metabolism to facilitate glutathione regeneration and thereby free-radical control (71).
respectively (54). Live (but not killed) \textit{M. leprae} promoted an M2-like phenotype in hMDM, based on IL-1β, IL-6, TNF, IL-10, CD163 and MHC-II expression (55). This M2-skewing was confirmed by measuring IL-10 and IL-12 transcript and protein levels in a different study (74). When \textit{M. leprae}-infected macrophages were exposed to naïve T cells, diminished pro-inflammatory responses together with increased T regulatory phenotypes were reported (55, 74). These changes occurred using \textit{M. leprae} harvested from both tuberculoid and lepromatous skin lesions (74). These findings suggest that the M2-like macrophages with predominant oxidative metabolism – same as in the context of \textit{M. tb} infection - would favour pathogen persistence rather than infection resolution.

Production of mycolactone by intracellular \textit{M. ulcerans} causes the apoptosis of host macrophages, and bacteria grow primarily extracellularly in infected skin during active BU (11). However, mycolactone released by bacteria diffuses broadly in infected organisms, interfering with the metabolism of both skin-resident and more distant cells (11, 75–77). Mycolactone-mediated Sec61 blockade is likely to impair host cell energy metabolism via the downregulation of nutrient transporters, such as the glucose transporter Glut1 (SLC2A1). In support of this hypothesis, our metabolomic analysis of Jurkat T cells exposed to mycolactone revealed decreased intracellular levels of Glut1 substrates, glucose-1-phosphate and mannose-6-phosphate, suggesting impaired glycolytic activity (77). We speculate that during infection with \textit{M. ulcerans}, inhibition of Sec61 impairs glycolysis reprogramming in infected macrophages, and more generally in all mycolactone-exposed immune cells.

**Lipid Metabolism**

In addition to reprogramming energetic metabolism, \textit{M. tb} infection rewires the lipid metabolism of host macrophages through inhibition of catabolic pathways (lipid droplet [LD] lysis and β-oxidation of fatty acids) and concomitant activation of lipid uptake, mobilization and de novo synthesis (78). This leads \textit{M. tb}-infected macrophages to acquire a foamy phenotype, due to the cytoplasmic accumulation of LDs mainly composed of triacylglycerol (TAGs), a storage form of fatty acids, and cholesteryl esters. Whether LD accumulation is beneficial to host macrophages or intracellular \textit{M. tb} is a matter of debate. Since intracellular \textit{M. tb} has the ability to import fatty acids deriving from host TAGs and foamy macrophages are a hallmark of chronic TB, accumulation of LDs in infected macrophages may provide the pathogen with essential nutrients (37, 79–81). However, recent data indicate that LD maintenance requires IFNγ-driven induction of HIF-1α, which inhibits lipolysis and prevents \textit{M. tb}'s acquisition of host lipids (82). Besides, LDs are the major sites of eicosanoid production including the anti-mycobacterial prostaglandin E2 (PGE2) (83), and have direct antibacterial properties (84). PGE2 is required for \textit{M. tb} control (85, 86) Leukotriene B4 (LTB4) is elevated in pulmonary TB compared to latent \textit{M. tb} infected individuals (LTBI) (87) and contributes to \textit{M. tb} immunopathogenesis (86). Beside eicosanoids, fatty acids released by LD lysis can be shuttled across the mitochondrial cell wall for β-oxidation, generating acetyl-CoA that enters the TCA cycle, and co-enzymes used in the respiratory chain to produce ATP. Interestingly, inhibiting fatty acid oxidation augmented macrophage ability to control \textit{M. tb} infection (30, 53). Rather than starving intracellular \textit{M. tb} from lipid nutrients, blocking β-oxidation of fatty acids may favour the generation of mitochondrial ROS that promote the phagosomal recruitment of NADPH oxidase and the xenophagic elimination of \textit{M. tb} (53).

Similar to \textit{M. tb}, \textit{M. leprae} upregulates lipid uptake and biosynthetic pathways in infected macrophages, particularly cholesterol (88, 89). Mechanistically, infection with \textit{M. leprae} increases macrophage expression of scavenger receptor (SR)A-I and CD36, promoting the foamy macrophage phenotype (90, 91). The mycobacteria seem to take shelter within lipid bodies, formed abundantly by host cells, possibly as a strategy to cover and hide surface antigens from innate immune receptors in the cytosol (92, 93). Contrary to \textit{M. tb} (94), \textit{M. leprae} cannot degrade or utilize cholesterol as a nutritional source (92), leaving the mechanism by which host cholesterol metabolism supports its in vivo persistence undefined. Notably, \textit{M. leprae} infection reduces host cell mitochondrial activity in a distinctive manner (88). Oliveira et al. proposed that cytosolic accumulation of lipids in \textit{M. leprae}-infected macrophages may contribute to mitochondrial shutdown and suppression of their innate immune functions (88).

Besides, macrophages infected with \textit{M. tb} deprive intracellular bacteria from essential micronutrients like iron and manganese, while using copper and zinc to poison them (95). In turn, \textit{M. tb} has developed sophisticated strategies to ensure micronutrient acquisition and resist metal toxicity. Interestingly, iron release prevails in AMs facilitating \textit{M. tb} access to iron, whereas IMs have the capacity to sequester it, contributing to an iron starvation \textit{M. tb} phenotype (96). Further information on this topic can be found in an excellent recent review by Neyrolles et al. (95). Proteins involved in iron uptake and metabolism are upregulated in lepromatous leprosy lesions, compared to tuberculoid forms, suggesting an association between iron storage in \textit{M. leprae}-infected macrophages and intracellular bacterial persistence (97).

Together, these studies revealed aerobic glycolysis and fatty acid oxidation as key metabolic pathways enhancing or decreasing the anti-mycobacterial responses of macrophages, respectively. They highlighted species-specific mechanisms used by \textit{M. tb}, \textit{M. leprae} and \textit{M. ulcerans} to subvert the glycolytic switch that is induced by TLR stimulation in infected macrophages, and take advantage of the increased lipid anabolism in host macrophages.

**METABOLIC-EPIGENETIC CROSSTALK IN MYCOBACTERIAL-INFECTED MACROPHAGES**

The macrophage metabolic adaptations to mycobacterial infection translate into changes of the intracellular metabolome. The concentration of particular metabolites therefore increases with the predominance of certain metabolic pathways. For example, lactate generation is enhanced with glycolysis, and so are citrate and acetyl-CoA with an active TCA cycle. These metabolic intermediates have the potential to...
post-translationally modify a wide range of proteins (e.g. histones), increasing proteome diversity and modulating function, including immune function, according to the cell needs (98–100). DNA and histones can thus be modified through metabolic substrates (e.g. methionine, acetyl-CoA, lactate), and metabolic genes can also be targets of such modifications (101). There is increasing recognition that epigenetics play an important role in shaping host-pathogen interactions and infection outcomes.

Zhang and colleagues showed that macrophage histones can be lactylated promoting an M2-like phenotype upon bacterial challenge (102), although this idea has been recently challenged (103). Since elevated glycolysis and lactate production occur in the lung of M.tb-infected hosts [reviewed in (104)], lactate could potentially drive macrophages towards an M2-phenotype, favouring M.tb survival.

M.tb components switch host cellular metabolism toward aerobic glycolysis in human peripheral blood mononuclear cells (PBMC) through a TLR2-dependent but NOD2-independent mechanism which is partly mediated via the activation of the AKT/mTOR pathway (58). This seems to be of functional relevance as inhibition of the AKT/mTOR pathway inhibits cellular responses to M.tb both in human PBMC and a murine model of TB (58). Insights into the possible mechanisms underlying this relationship has come from studies of BCG vaccination, which has been shown to be a potent inducer of trained immunity due to cellular metabolism reprogramming arising from epigenetic changes (105). BCG-stimulated monocytes have been shown to undergo chromatin remodeling due to histone modification, namely increases in H3K4me3 and H3K9me3 at promoter sites of essential glycolytic genes. The resultant activation of the AKT/mTOR/HP1-1 pathway switches cellular metabolism from oxidative phosphorylation to aerobic glycolysis and as a consequence facilitates increased production of cytokines such as TNF and IL-6 that promote mycobacterial killing (106, 107). Conversely, these epigenetic changes are dependent on the induction of metabolic processes, as inhibition of glycolysis results in reversal of changes in H3K4me3 and H3K9me3 at promoter sites of TNF and IL-6 (107). In contrast to BCG, M.tb has been shown to impair macrophage trained immunity through activation of the type I interferon/iron axis in hematopoietic stem cells (108). This immune-metabolic reprogramming also resulted in suppressed myelopoiesis, overall enhancing host susceptibility to M.tb infection (108).

Another recently described epigenetic modification shown to cause immunomodulation in M.tb infection involves Alu repeat elements. Alu repeats are mobile interspersed repetitive DNA sequences that are transposable from one site in the genome to another, resulting in mutations, insertions and recombination events in protein-coding mRNAs (109). Analysis of genes adjacent to H3K4me1-associated Alu repeats linked to macrophage metabolic responses to M.tb infection has shown that Liver X Receptor-α signaling can be initiated at response elements present in Alu repeats and significantly reduces M.tb viability by altering cholesterol metabolism and enhancing macrophage apoptosis (110). Furthermore, levels of Alu methylation have been found to be significantly lower in paediatric TB patients and the detection of Alu DNA methylation may serve as a diagnostic and prognostic tool of TB disease in this population (111).

**CO-MORBIDITIES IMPACT ON METABOLISM AND IMMUNITY**

Vulnerability to infection with M.tb and progression to active disease can be affected by several co-morbidities and social risk factors. The main co-morbidities associated with TB progression and poor outcomes are HIV infection, diabetes, renal disease and smoking. Social risk factors such as excess alcohol consumption, air pollution, incarceration and poor housing are also important. Diabetes, tobacco smoking and HIV infection have a profound impact on the host metabolic state, at both the macrophage (Figure 2) and systemic levels. Understanding how these metabolic changes occur will contribute to elucidating why these particular conditions worsen TB.

**Smoking**

The fact that tobacco smoking impacts the immune system and increases the prevalence of both respiratory and distal organ-associated diseases has been known for decades [reviewed in (112–116)]. Cigarette smoke (CS) contains abundant...
compounds (including toxins and carcinogens) which can directly modify immune function [reviewed in (115)].

Few studies have investigated the direct metabolic impact of smoking in M.tb infection. A macrophage shift to glycolysis is essential for effective control of M.tb (30, 47, 49). AMs from smokers presented decreased capacity to control H37Rv M.tb compared to non-smokers (117). This was probably due to impaired secretion of key cytokines for infection control, including IL-1β, TNF and IFNγ, and some of these altered immune responses remained in AMs from ex-smokers (117).

Both reduced metabolic activity (measured by oxygen consumption rate [OCR] and extracellular acidification rate [ECAR]) and metabolic reserves (glycolytic reserve and spare respiratory capacity [SRC]) have been reported at baseline in AM from smokers, measured by extracellular flux analysis (33). Interestingly, baseline metabolism of smokers’ AMs was skewed towards glycolysis, matching previous results (118). AMs from smokers showed diminished glycolysis than AMs from non-smokers when challenged with M.tb, measured by extracellular flux analysis (33). No differences in oxidative metabolism were detected. Of note, the essential shift towards glycolysis (ECAR/OCR) for M.tb control was severely impaired in smokers’ AMs compared to their non-smokers counterparts, and was confirmed at the transcriptional level (2-fold change reduction in the glycolysis rate-limiting enzyme hexokinase 1). This translated in a trend towards attenuated pro-inflammatory responses (IL-1β and PGE2 secretion). The described deficient shift to glycolysis, decreased lactate and IL-1β secretion were confirmed in an in vitro model of hMDMs treated with CSE (33). The bioenergetic profiling experiments were performed using H37Rv γ-irradiated M.tb. This is important since live/dead M.tb have been shown to induce profoundly different metabolic adaptations in hMDMs measured by extracellular flux analysis (48). Other studies using hMDM and a THP-1 model and CSE have shown impaired responses to LPS, based on reduced basal and induced glycolysis, NLRP3 activation and subsequent IL-1β and IL-18 secretion (119).

Although further mechanistic studies are needed, there is enough evidence supporting the notion that CS causes dysfunctional AM metabolic profiles, which directly impact the orchestration of effective immune responses against respiratory pathogens, and might help explaining the worsening of TB reported in the smoking population.

Diabetes Mellitus
The Increasing Overlap of Two Epidemics
Up until a few years ago, the epidemics of TB and diabetes mellitus (DM) were, for the most part, geographically disconnected. Today, the geographic overlap between these two epidemics arises as a worldwide threat, as TB and diabetes have the potential to make each other worse (120, 121). It is estimated that about 15% of current TB cases are associated with T2D (122, 123). Here, we will discuss how diabetes detrimentally impacts TB.

Animal studies have further confirmed that DM worsens TB outcomes. In a mouse model of DM using streptozotocin (STZ) to destroy pancreatic islets, macrophages presented a 90% reduction in their phagocytic capacity, although their intracellular killing abilities were intact (124). When these mice were challenged with M.tb (Schacht strain) 90% of them died, compared to 10% in the non-diabetic group (124). Other mice, rat and guinea pig models of diabetes/hyperglycaemia have reported increased bacterial burden compared to control animals, together with diminished IFNγ responses (125–129).

Immune Alterations
Chemotaxis of monocytes has been shown to be impaired in diabetic patients (130, 131), potentially affecting recruitment into the lung. Furthermore, monocytes from DM patients presented diminished binding and phagocytic capacity towards H37Rv M.tb compared to healthy controls (132).

Within the lungs of diabetic C57BL/6 mice (STZ model) and using an aerosol challenge model of Erdman M.tb, it was shown that the increased TB susceptibility may arise from delayed innate immune responses (133). In particular, at 2 weeks post-infection (pi) there was abundant recruited monocytes at the site of infection in the control group. In contrast, in the lungs of diabetic mice, M.tb-infected AMs prevailed, and monocyte recruitment was limited (133). This translated in delayed delivery of M.tb-antigens to the lymph nodes, and delayed presence of IFNγ M.tb-specific T cells in the lymph nodes and in the lungs compared to the non-diabetic group, slowing appearance of effective immune responses and potentially contributing to bacterial persistence (133). The mechanisms underlying impaired chemotaxis/recruitment remain unknown. The reliance of AMs on oxidative metabolism which facilitates M.tb persistence, in comparison to the more glycolytic recruited monocytes, could further explain the observed differences in mycobacterial control.

PBMCs from healthy individuals treated with M.tb lysate in high concentrations of glucose (40mM, but not 25mM or lower) resulted in increased secretion of TNF, IL-1β, IL-6, but not IFNγ IL-17A and IL-22 (134). Differentiated macrophages at 25 mM glucose promoted enhanced cytokine production after stimulation with M.tb lysate and LPS. However, no differences were reported in phagocytosis and M.tb killing capacities (134). Macrophages differentiated from healthy individuals and diabetic patients were characterised at baseline and after M.tb infection (MOI 5:1 for 24h) with different strains (135). Expression of key molecules for antigen presentation (HLA-DR, CD80 and CD86), the inhibitory molecule PD-L1, and cytokines/chemokines secretion patterns differed between DM patients and controls. MDMs from T2D patients presented attenuated capacity to bind, internalise and clear M.tb, and worse outcomes were reported with more virulent strains (135). Similarly, MDMs from chronic diabetic patients presented impaired M.tb killing capacity (136). Monocytes from T2D patients and healthy controls infected with M.tb presented similar bacterial growth (137). However, monocytes cultured at 30mM glucose to mimic hyperglycaemic conditions, compared to monocytes cultured at 11mM glucose, presented decreased IL-8 production (a key neutrophil chemoattractant) as well as increased H37ra M.tb survival 3 days pi (137).

In the particular context of AM, TB-DM patients presented decreased numbers of a particular hypodense AM subset, compared to TB only patients (138). Within the active pulmonary TB patients, a negative correlation was observed between the percentage of...
hypodense AMs and sputum bacterial load, together with disease severity assessed by chest X-ray. Overall AMs from TB-DM patients were less activated (138). Although primarily reporting descriptive findings, this is, to our knowledge, the first study showing direct impact of DM in the AM lung-resident population. Another key study focusing on AMs used the STZ mice diabetes model and showed that AMs from diabetic mice presented reduced CD14 and MARCO expression, the latter being essential in the recognition of trehalose 6,6′-dimycocatal (TDM) within the bacterial cell wall (139). This translated in reduced M.tb (Erdman strain) phagocytosis and was specific to the AM population (peritoneal or BMDM did not present this altered phenotype). These AMs defects resulted in impaired T-cell priming, which was observed when AMs from diabetic animals were transferred to control animals (139).

Other major immune cell types including dendritic cells, neutrophils, natural killer cells and T cells are also impacted in the context of diabetes and hyperglycaemia. It is beyond the scope of this review to explore their precise mechanisms, and they have been reviewed elsewhere (140, 141).

**Immune-Metabolic Alterations Beyond Hyperglycaemia**

DM not only comprises hyperglycaemia but also a wide range of further metabolic alterations [reviewed in (142)] which have the potential to impact immune responses to M.tb (i.e. dyslipidaemia, redox and hormone balance). DM is often associated with dyslipidaemia (e.g. increased oxidised-low density lipoproteins [ox-LDLs]) and although it is difficult to establish causal links, it is well described that M.tb thrives in lipid-rich environments. Ox-LDLs accumulate in AMs of guinea pigs infected with M.tb, increasing bacterial burden (143). Similarly, in vitro human studies showed that ox-LDLs promoted M.tb survival by impairing lysosomal function (144).

It is challenging to draw conclusive answers regarding the underlying mechanisms of TB enhanced susceptibility in DM patients due to the limited number of human studies and the variety of models used (i.e. mouse and human monocytes/macrophages, from diabetic subjects or treated with varying concentrations of glucose). Nonetheless, there is ample evidence suggesting altered function of the myeloid compartment in the context of DM, including chemotaxis, bacterial recognition, phagocytosis, cytokine secretion and metabolism, which could facilitate TB disease. The described immune alterations have the potential to impact the outcome of other infectious diseases [reviewed in (145, 146)]. Although there is scarce literature exploring the link between diabetes and leprosy, early studies reported an increase in diabetes in lepromatous leprosy patients (147).

**HIV**

According to the WHO, people living with HIV have an increased risk (16–27 times) of developing active TB compared to non-infected individuals (2). One of the key mechanisms behind this enhanced risk is the fact that HIV causes CD4+ T cell depletion [reviewed in (148)], a cell subset essential for control of M.tb infection (149–151). There is increasing awareness of HIV-driven impairment in the innate immune compartment as a key contributor to increased TB risk in M.tb-infected individuals. Here, we explore the impact of HIV infection on macrophages and how that may facilitate TB progression.

Monocyte chemotaxis (152) and monocyte oxidative burst capacities have been shown to be impaired in HIV-infected individuals (153). HIV infection downregulated essential TLRs in the myeloid compartment which are essential for M.tb recognition (154, 155). In vitro, HIV infection of hMDMs promotes an M1-like phenotype (156) and impacts macrophage metabolism, inducing mitochondrial fusion, reduced oxidative phosphorylation and no changes in glycolysis (157, 158). Enhanced lipid accumulation together with increased uptake of ox-LDL was reported in hMDMs from HIV-infected individuals compared to controls, which could potentially contribute to the foamy macrophage phenotype and aid M.tb survival (159). HIV-infected hMDMs prevented GM-CSF-mediated activation of STAT5A, a signalling pathway essential for TB control (160). TNF secretion was reduced in HIV/M.tb co-infected macrophages compared to M.tb alone in a THP-1 cell model and human AMs (161, 162), as well as TNF-dependent apoptosis (161–163). There is evidence of HIV capacity to infect AMs (164, 165) which can act as viral reservoirs (166). HIV-infected AMs present impaired phagocytic function (167), and HIV inhibits phagocytosis in hMDMs in a Nef-dependent manner (168). Restricted vesicle acidification in AMs from HIV-TB patients has been reported (169). One study in HIV-TB coinfected individuals reported no differences in phagocytosis or acidification capacities due to HIV infection (170). The overall evidence suggests that HIV makes AMs more permissive to M.tb and promotes early bacterial growth, but further research is needed to precisely elucidate the role of macrophage metabolism in this co-infection setting.

In contrast to TB, an increased risk of leprosy or enhanced severe disease has not been described in HIV-infected individuals [reviewed in (171)]. However, leprosy patients receiving highly active antiretroviral therapy (HAART) are at increased risk of reversal reaction (RR), an inflammatory exacerbation (172). The monocyte/macrophage phenotype has been shown to be distinct in skin lesions from RR/HIV patients compared to RR alone (173) including increased expression of CD209, vascular endothelial growth factor (VEGF), arginase 2 (ARG2) and PPARy in the former. The clinical implications of these findings remain unknown. HIV-BU co-infection is rare and there is very limited research on the topic. However, current studies point towards BU patients being more likely to be infected with HIV, and HIV infection increasing BU severity (174, 175).

**IDENTIFYING IMMUNE-METABOLIC HOST THERAPEUTIC TARGETS**

Given the significant disease burden of TB and leprosy, the rise in drug resistance and the challenges associated with the development of novel anti-mycobacterial agents, HDT strategies which augment host responses to mycobacterial infections, have become an increasing focus of interest (176–178) (Figure 3). Greater understanding of the role of immunometabolism in both protection against, and susceptibility to, infection provides potential targets to promote resistance and modulate tolerance to chronic infection.
As discussed, it is well established epidemiologically that individuals with metabolic conditions such as T2D are at increased risk of developing active TB disease, suggesting not only the important role of host metabolic regulation in anti-M.tbc responses but also pathways for possible therapeutic intervention (179).

In the context of T2D, the antihyperglycemic biguanide drug metformin appears to be a good candidate to modulate mycobacterial tolerance [reviewed in (180)]. Among patients with T2D metformin reduces the risk of M.tbc infection, the progression to and the severity of TB disease, mortality, lung cavitation, relapse, accelerates sputum conversion and enhances the efficacy of anti-TB drugs (181–186). Several possible mechanisms for the advantageous effects of metformin have been suggested, including enhancing phagocytosis, phagolysosome fusion and autophagy to increase M.tbc killing in macrophages; the upregulation of mitochondrial ROS production and intracellular antimycobacterial responses; an anti-inflammatory effect to reduce deleterious inflammation (182, 187, 188). Recent work suggests that metformin also educates CD8+ T-cells which results in increased mitochondrial mass, oxidative phosphorylation, and fatty acid oxidation. Such reprogramming of immune-metabolic circuits increases survival capacity and antmycobacterial properties of CD8+ T-cells, as seen by enhancement of BCG vaccine protective efficacy and improvements in the sterilizing ability of antibiotics (189). Since butyrate increases susceptibility to TB (134), increasing its concentration by altering gut microbiota might offer another HDT against M.tbc. Eicosanoids have also been proposed as potential drug candidates for treating TB. In elegant mice experiments, IL-1 induced PGE2 production which promoted M.tbc control by suppressing type I IFN (85). Furthermore, PGE2 administration resulted in decreased pulmonary M.tbc load and associated pathology, as well as increased animal survival (85). These promising findings need to be validated in humans and recent evidence highlights the potential of PGE2 as an HDT candidate for treating TB (190). However, a comprehensive understanding of PGE2 kinetics and its effects on the overall immune system will be needed before eicosanoids can be clinically applied (191).

Similar to the action of metformin in targeting whole-body metabolism, statin intake has been associated with significantly reduced risk of developing TB in both T2D patients and non-diabetic general populations (192). Statins reduce inflammation, modulate the immune responses and have direct antimicrobial effects (193). Used as an adjunct, statins enhance the bactericidal activity of first-line TB drugs against intracellular M.tbc and shortens TB treatment duration (194). Mechanistic studies indicate that statin-mediated reduction in cholesterol levels within phagosomal membranes counteract M.tbc-induced inhibition of phagosomal maturation and promotes host-induced autophagy, therefore augmenting host responses against M.tbc (195).

The role of vitamins in host immunity to M.tbc are of increasing interest. The active form of vitamin A, all-trans retinoic acid (ATRA), has been shown to promote autophagy. This results in a reduced bacterial burden in human macrophages infected with M.tbc, which is induced by cytosolic sensing of double-stranded DNA via the STING/TK1/IRF3 axis (196). Furthermore, ATRA induces a reduction in total cellular cholesterol concentration and promotes lysosomal acidification in M.tbc-infected monocytes via an NPC2-dependent mechanism which results in enhanced antimicrobial activity (197). The possible benefit derived from sunlight and vitamin D supplementation was first suggested in the pre-antibiotic era and has shown to modulate both innate and adaptive immune responses. The biologically active form of vitamin D, 1,25-dihydroxy- vitamin D3 (1,25(OH)2D3), enhances the expression of LL-37 in macrophages, the only cathelicidin-derived antimicrobial peptide found in humans, which promotes the destruction of M.tbc and consequently autophagy (198, 199). While a series of clinical trials have failed to show vitamin D supplementation impacts on clinical outcomes in TB, there is some
evidence that high-dose vitamin D improves the resolution of inflammatory responses during TB therapy and may be beneficial in a subset of TB patients who have a specific polymorphism in the vitamin D receptor (VDR) (200, 201).

The exploration of possible roles of immunomodulatory macronutrient has, to date, focused on glutamine, arginine and tryptophan. Glutamine pathway genes are differentially expressed in \textit{M. tb}-infected macrophages and in the blood of individuals with LTBI or active TB. Glutamine has been identified as the main nitrogen \textit{M. tb} source within infected macrophages (202). Inhibiting glutaminolysis or reducing the availability of glutamine impairs the production of key cytokines by T-cells (IFN\gamma, IL-1\beta, IL-17 and IL-22) in response to challenge with \textit{M. tb}, as does genetic polymorphisms in glutamine metabolism genes (including GLS2, SLC1A5, and SLC7A5) (203). Similarly, L-citrulline and L-arginine are necessary for antimycobacterial responses, mediated by microbicidal NO production via inducible NO synthase–mediated L-arginine metabolism in infected macrophages. It has been suggested that targeting this pathway might provide novel approaches for enhancing immunity in mycobacterial disease (204). Interestingly, Arg1 conditional gene-deleted mice presented decreased \textit{M. tb} burden compared to wild types, probably due to enhanced macrophage \textit{M. tb} killing capacities (205). In contrast, L-Arg has been shown to contribute to macrophage \textit{M. tb} clearance (206). Observed differences could be explained by different location of Arg1+ macrophages within the granuloma, as well as their role in different infection stages (207). Finally, tryptophan biosynthesis by mycobacteria under stress conditions has been shown to protect \textit{M. tb} from CD4+ T-cell-mediated killing by IFN\gamma. Inhibition of \textit{M. tb} tryptophan synthase by the small-molecule 2-amino-6-fluorobenzoic acid (6-FABA) converts \textit{M. tb} into a tryptophan auxotroph and restores the efficacy of failed CD4+ T-cell-mediated host defence (208). Interestingly, the indole propionic acid (IPA), produced by the gut microbiota, also blocks tryptophan biosynthesis in \textit{M. tb} via inhibition of anthranilate synthase (TrpE) which catalyses the first committed step in the tryptophan biosynthesis pathway, by mimicking the physiological allosteric inhibitor of this enzyme (209). Therefore, in contrast to macronutrient supplementation by glutamine and arginine, tryptophan depletion may have a role in \textit{M. tb} control. In the specific context of macrophages, \textit{M. tb} infection causes indoleamine 2,3-dioxygenase (IDO) upregulation, the first rate-limiting enzyme of tryptophan catabolism (210, 211). This not only decreases tryptophan concentrations, but also produces metabolites which activate the aryl hydrocarbon receptor (AHR), which in turns modulate immune activity. For instance, Ahr\textsuperscript{-/-} mice were unable to control \textit{M. tb} H37Rv infection (212). Excellent recent reviews have further covered the potential intervention of metabolic pathways for HDT against TB (213–216).

Treating infected macrophages with statins reduces the viability of intracellular \textit{M. leprae}, similar to that seen with \textit{M. tb}, raising the possible use of statins as an adjuvant HDT for leprosy (217). Also similar to \textit{M. tb}, autophagy is an exciting possible target for HDT leprosy as it promotes bacterial clearance and antigen presentation (218, 219). Not only does autophagy clear \textit{M. leprae} from macrophages but recent evidence suggests it can modulate leprosy disease presentation, driving paucibacillary tuberculoid leprosy in individuals with more autophagic control with a predominance of IL-26, IFN\gamma, and TNF, autophagy-inducing cytokines (51, 220–223). Rapamycin, metformin and the antiprotozoal drug nitazoxanide have been proposed as HDTs against leprosy via modulating autophagic mechanisms to promote the antimicrobial response against \textit{M. leprae} and decrease inflammation-mediated immunopathology (93).

CONCLUSION

Mycobacterial infections still represent a major public health issue and we need better treatments. A greater understanding of the host-induced metabolic and immune responses to mycobacterial challenge will aid the design of novel, and needed, host-directed therapeutic strategies. Macrophages are mycobacterial targets and constitute a heterogeneous cell population; as reflected by their metabolic diversity and plasticity. Mycobacterial infection shapes host cell metabolism and there are clear metabolic and coupled functional phenotypes associated with particular infection outcomes (ie. M1-like favours infection control, while M2-like macrophages are more permissive to infection). Changes in macrophage polarisation upon infection directly impact the concentration of certain intracellular metabolites. They have the potential to post-translationally modify proteins, including histones. Therefore, changes in host cell metabolism can change the epigenetic landscape of the cell, with long term consequences regarding the host ability to control mycobacterial infection (107, 108). Mycobacterial diseases including TB and leprosy do not exist in isolation. Co-morbidities such as smoking, diabetes and HIV infection can worsen TB outcomes, and this can partially be explained by disease-induced metabolic changes. Gaining mechanistic understanding of this phenomenon brings us closer to the design of new and effective therapies, including expanding the use of current drugs such as metformin. There has been outstanding research in the last decades unravelling the links between cell metabolism and induced immune responses. This is a promising avenue that needs pursuing as it holds great potential to identify new targets for therapy that will aid the fight against ancient and devastating epidemics such as TB and leprosy.

AUTHOR CONTRIBUTIONS

AL and CM conceptualised the manuscript. AL, MD, JB, CD, MO’S, and CM wrote the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

AL is supported by the European Commission (H2020-761 MSCA-IF-2018, 841729). CM is supported by the Medical Research Council (MR/T016736/1) and by a Professorial Fellowship and Translational Funds from the University of Birmingham.
REFERENCES

1. Zink AR, Sola C, Reischl U, Grabner W, Rastogi N, Wolf H, et al. Characterization of Mycobacterium Tuberculosis Complex Dnas From Egyptian Mummies by Spoligotyping. *J Clin Microbiol* (2003) 41(1):359–67. doi: 10.1128/JCM.41.1.359-367.2003

2. World Health Organization. Global Tuberculosis Report, Vol. 2020. (2020).

3. Thekkur P, Tewya H, Phiri S, Mpunga J, Kalua T, Kumar AMV, et al. Assessing the Impact of Covid-19 on Tb and Hiv Programme Services in Selected Health Facilities in Lilongwe, Malawi: Operational Research in Real Time. *Trop Med Infect Dis* (2021) 6(2):1–16. doi: 10.3390/tropicalmed6020081

4. World Health Organization. Towards Zero Leprosy Towards Zero Leprosy - Global Leprosy (Hansen’s Disease) Strategy 2021–2030. (2021). Available at: https://www.who.int/publications/i/item/9789290228509

5. Dops P, Geura P, Nasser S, Simon M. Hemolytic Anemia in Patients Receiving Daily Dapsone for the Treatment of Leprosy. *Lepr Rev* (2012) 83(3):305–7. doi: 10.4772/lepr.83.3.305

6. Achkar JM, Jenny-Avital ER. Incipient and Subclinical Tuberculosis: Defining Early Disease States in the Context of Host Immune Response. *J Infect Dis* (2011) 204(SUPPL. 1):1179–86. doi: 10.1093/infdis/jir541

7. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al. Tuberculosis. *Nat Rev Dis Prim* (2016) 2:21–23. doi: 10.1038/nrdp.2016.76

8. Gaschignard J, Grant AV, Van Thuc N, Orlowa M, Cobat A, Huong NT, et al. Pauci- and Multibacillary Leprosy: Two Distinct, Genetically Nondissected Diseases. *PloS Negl Trop Dis* (2016) 10(5):1–20. doi: 10.1371/journal.pntd.0003435

9. da Silva Prata RB, de mattos Barbosa MG, de Andrade Silva BI, Paixao de Oliveira JA, Lameira Bittencourt T, Olmo Pinheiro R. Macrophages in the Pathogenesis of Leprosy. *IntechOpen* (2016) 1:1–19. doi: 10.5772/intechopen.88754

10. Tortoli E, Fedrizzi T, Meehan CJ, Trovato A, Grotta C, Giacobazzi E, et al. The New Phylogeny of the Genus Mycobacterium: The Old and the New. *Infect Genet Evol* (2017) 56(October):19–25. doi: 10.1016/j.megev.2017.10.013

11. Demangel C. Immunity Against Mycobacterium Ulcerans: The Subversive Role of Mycolactone. *Immunol Rev* (2020) 301(1):209–11. doi: 10.1111/imr.12217

12. Omansen TF, Erbowor-Becksen A, Yotsu R, van der Werf TS, Tiendrebeogo Kasperbauer SH, Daley CL. Mycobacterium Chimaera Infections Related to Alveolar Macrophages Provide an Early Mycobacterium Tuberculosis Niche and Initiate Dissemination. *Cell Host Microbe* (2020) 18(3):439–46. doi: 10.1016/j.chom.2018.08.001

13. Davey T, Rees R. The Nasal Dicharge in Leprosy: Clinical and Bacteriological Aspects. *Lepr Rev* (1974) 45(2):121–34. doi: 10.9353/jcm.0305-7518.19740014

14. Scollard DM, Adams LB, Gillis TP, Krakenhulb JL, Truman RW, Williams DL. The Continuing Challenges of Leprosy. *Clin Microbiol Rev* (2006) 19(2):338–81. doi: 10.1128/CMR.19.2.338-381.2006

15. Bratschi MW, Steinmann P, Wickenden A, Gillis TP. Current Knowledge on Mycobacterium Leprae Transmission: A Systematic Literature Review. *Lepr Rev* (2015) 86(2):142–55. doi: 10.47276/lepr.86.2.142

16. Torrado E, Fraga AG, Castro AG, Strager P, Meyers WM, Portals F, et al. Evidence for an Intramacrophage Growth Phase of Mycobacterium Ulcerans. *Infect Immun* (2007) 75(2):977–86. doi: 10.1128/IAI.00889-06

17. Philips JA, Ernst JD. Tuberculosis Pathogenesis and Immunity. *Annu Rev Path Mech Dis* (2012) 73:589–83. doi: 10.1146/annurev-pathmech-011112-120435

18. Marakalala MJ, Martinez FO, Pfddemann A, Gordon S. Macrophage Heterogeneity in the Immunopathogenesis of Tuberculosis. *Front Microbiol* (2018) 9:1–15. doi: 10.3389/fmicb.2018.01022

19. Huang L, Nazarova EV, Tan S, Liu Y, Russell DG. Growth of Mycobacterium Tuberculosis In Vivo Segregates With Host Macrophage Metabolism and Ontogeny. *J Exp Med* (2018) 215(4):1135–52. doi: 10.1084/jem.20172020

20. Gordon S. Alternative Activation of Macrophages. *Nat Rev Immunol* (2003) 3(1):23–35. doi: 10.1038/nri978

21. Guirado E, Schlesinger LS, Kaplan G. Macrophages in Tuberculosis: Friend or Foe. *Semin Immunol* (2013) 25:563–83. doi: 10.1016/j.simp.2013-0388-2

22. Gleson LE, O’Leary SM, Ryan D, McLaughlin AM, Sheedy FJ, Keane J. Cigarette Smoking Impairs the Bioenergetic Immune Response to Mycobacterium Tuberculosis Infection. *Am J Respir Cell Mol Biol* (2018) 59(5):572–9. doi: 10.1165/rcmb.2018-0162OC

23. Tan SYS, Krasnow MA. Developmental Origin of Lung Macrophage Diversity. *Dev* (2016) 143(8):1318–27. doi: 10.1242/dev.129122

24. Gibbings SL, Thomas SM, Atif SM, McCubrey AL, Desch AN, Danhorn T, et al. Three Unique Interstitial Macrophages in the Murine Lung at Steady State. *Am J Respir Cell Mol Biol* (2017) 57(1):66–76. doi: 10.1165/rcmb.2016-03610C

25. Srivastava S, Ernst JD, Desvignes L. Beyond Macrophages: The Diversity of Mononuclear Cells in Tuberculosis. *Immunol Rev* (2014) 262(1):179–92. doi: 10.1111/imr.12217

26. Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. Foamy Macrophages and the Progression of the Human Tuberculosis Granuloma. *Nat Immunol* (2009) 10(9):943–8. doi: 10.1038/ni.1781

27. Chambers T, Spector W. Inflammatory Giant Cells. *Immunobiology* (1982) 161(3–4):293–9. doi: 10.1007/BF0171-2983(82)00084-3

28. Moura DF, de Mattos KA, Amadeu TP, Andrade PR, Sales JS, Schmitz V, et al. CD163 Favors Mycobacterium Leprae Survival and Persistence by Promoting Anti-Inflammatory Pathways in Lepromatous Macrophages. *Eur J Immunol* (2012) 42(11):2925–36. doi: 10.1002/eji.201142198

29. Guarner J, Buruli Ulcer: Review of a Neglected Skin Mycobacterial. *J Clin Microbiol* (2018) 2(3):1–8. doi: 10.1128/JCM.01507-17

30. Baron L, Paeter MO, Morel JD, Impens F, Guerin-Macc L, Saint-Auret S, et al. Mycolactone Subverts Immunity by Selectively Blocking the Sec61 Translocon. *J Exp Med* (2016) 213(13):2885–96. doi: 10.1084/jem.20160662

31. Demangel C, High S. Sec61 Blockade by Mycolactone: A Central Mechanism of Human Macrophage Activation. *Immunity* (2014) 40(2):274–88. doi: 10.1016/j.immuni.2014.01.006

32. Martinez FO, Gordon S. The M1 and M2 Paradigm of Macrophage Activation: Time for Reassessment. *F1000Prime Rep* (2014) 6:1–13. doi: 10.12703/P6-13

33. McKenna M, Simmonds RE, High S. Mechanistic Insights Into the Inhibition of Sec61-Dependent Co- and Post-Translational Translocation by Mycolactone. *J Cell Sci* (2016) 129(7):1404–15. doi: 10.1242/jcs.182352

34. McKenna M, Simmonds RE, High S. Mycolactone Reveals the Substrate-Driven Complexity of Sec61-Dependent Transmembrane Protein Biogenesis. *J Cell Sci* (2017) 130(7):1307–20. doi: 10.1242/jcs.198655
45. Hall BS, Hill K, McKenna M, Ogbechi J, High S, Willis AE, et al. The Pathogenic Mechanism of the Mycobacterium Ulcers Virulence Factor, Mycolactone, Depends on Blockade of Protein Translocation Into the ER. *Plos Pathog* (2014) 10(4):15–7. doi: 10.1371/journal.ppat.1004061

46. Morel ID, Paetzer AO, Wei J, Yewdell JW, Guenin-Macé L, Van Haver D, et al. Proteomics Reveals Scope of Mycolactone-Mediated Sect21 Blockade and Distinctive Stress Signature. *Mol Cell Proteomics* (2018) 17(9):1750–65. doi: 10.1074/mcp.RA118.000824

47. Gleeson LE, Sheedy F, Palsson-McDermott EM, Triglia D, O, et al. The Essential Mediator of IFN-α Dependent Immunity to Mycobacterium Tuberculosis. *Infect Immun* (2016) 84(9):9368–78. doi: 10.1128/IAI.01914-14

48. Olson GS, Murray TA, Jahn AN, Mai D, Diercks AH, Gold ES, et al. Type I Interferon Decreases Macrophage Energy Metabolism During Mycobacterial Infection. *Cell Rep* (2020) 11(4):1–15. doi: 10.1016/j.celrep.2020.03.057

49. Fulco T de O, Andrade PR, Barbosa MG de M, Pinto TGT, Ferreira PF, Costa S, et al. Mycobacterium Leprae-Induced Insulin-Like Growth Factor I Attenuates Antimicrobial Mechanisms, Promoting Bacterial Survival in Macrophages. *Sci Rep* (2016) 6:21979. doi: 10.1038/srep21979

50. Chen SY, Wang Y, Lu M, Du X, Jin Y, et al. Mycolactone Diffuses Into the Peripheral Blood of Buruli Ulcer Patients - Role of Mycolactone in Modulating Human Monocytes. *Sci Rep* (2016) 6:13721. doi: 10.1038/srep33721

51. Schermerhorn HC, Gao C, Khanna A, Mokhtar S, et al. Mycolactone-Targeting Agents for the Treatment of Leprosy. *Mol Cell Proteomics* (2018) 17(9):2044–56. doi: 10.1074/mcp.M117.000842

52. Hackett EE, Sheedy FJ. An Army Marches on its Stomach: Metabolic Intermediates as Antimicrobial Mediators in Mycobacterium Tuberculosis Infection. *Front Cell Infect Microbiol* (2020) 10:603. doi: 10.3389/fcimb.2020.00603

53. Chandra P, He L, Zimmerman M, Yang G, Köster S, Ouimet M, et al. Metabolic Coordination of Macrophage Phagocytic and Antimicrobial Programs in Mycobacterial Infection. *Am Soc Microbiol Source* in Schwann Cells. *Intracellular Mycobacterium Leprae Utilizes Host Glucose as a Carbon Source in Schwann Cells. *Am Soc Microbiol* (2019) 10(6):1–9. doi: 10.1128/mbio.02351-19

54. Falows D, Peixoto B, Kaplan G, Manca C. Mycobacterium Leprae Alters Classical Activation of Human Monocytes In Vitro. *J Immunfl (United Kingdom)* (2016) 13(1):4–8. doi: 10.1186/s12950-016-0117-4

55. Yang D, Shui T, Miranda JW, Gilson DJ, Song Z, Chen J, et al. Mycolactone as a Nutrient-Rich Source in Schwann Cells. *Mol Cell Proteomics* (2018) 17(9):1750–65. doi: 10.1074/mcp.M117.000842

56. Leprosy Induces Decelerated Bioenergetic Metabolism in Human Macrophages. *Elife* (2018) 7:1–28. doi: 10.7554/elife.39169

57. Sheedy FJ, Divangahi M. Targeting Immunometabolism in Host Defence Against Mycobacterium Tuberculosis. *Infect Immun* (2021) 89(5):1672. doi: 10.1128/iai.00032-20

58. Nair S, Husain JP, Lampropoulou V, Logiacheva E, Esaulova E, Gounder AP, et al. Mycobacterium Tuberculosis Induces Decelerated Bioenergetic Metabolism in Human Macrophages. *Elife* (2018) 7:1–28. doi: 10.7554/elife.39169

59. Sheedy FJ, Divangahi M. Targeting Immunometabolism in Host Defence Against Mycobacterium Tuberculosis. *Infect Immun* (2021) 89(5):1672. doi: 10.1128/iai.00032-20

60. Hackett EE, Charles-Messance H, O’Leary SM, Gleeson LE, Munoz-Wolf N, Case S, et al. Mycobacterium Tuberculosis Limits Host Glycolysis and IL-10 Secretion by Restriction of PFK-M via MicroRNA-21. *Mol Cell Proteomics* (2018) 17(9):2044–56. doi: 10.1074/mcp.M117.000842

61. Sheedy FJ, Divangahi M. Targeting Immunometabolism in Host Defence Against Mycobacterium Tuberculosis. *Infect Immun* (2021) 89(5):1672. doi: 10.1128/iai.00032-20

62. Hackett EE, Sheedy FJ. An Army Marches on its Stomach: Metabolic Intermediates as Antimicrobial Mediators in Mycobacterium Tuberculosis Infection. *Front Cell Infect Microbiol* (2020) 10:603. doi: 10.3389/fcimb.2020.00603

63. Mills EL, Kelly B, Logan A, Costa ASH, Varma M, Bryant CE, et al. Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages. *Cell* (2016) 167(2):457–470.e13. doi: 10.1016/j.cell.2016.08.061
Acquires a Dormancy-Like Phenotype in Lipid-Loaded Macrophages. PloS Pathog (2011) 7(6):1–16. doi: 10.1371/journal.ppat.1002093

Knight M, Braverman J, Ashafa K, Gronert K, Stanley S. Lipid Droplet Formation in Mycobacterium Tuberculosis Infected Macrophages Requires IFN-γ/IFN-γR Signaling and Supports Host Defense. PloS Pathog (2018) 14(1):1006874. doi: 10.1371/journal.ppat.1006874

Mayer-Barber KD, Sher A. Cytokine and Lipid Mediator Networks in Tuberculosis. ImmunoL Rev (2015) 264(1):264–75. doi: 10.1111/imr.12249

Bosch M, Sánchez-Alvarez M, Fajardo A, Kapetanovic R, Steiner B, Dutra F, et al. Mammalian Lipid Droplets Are Innate Immune Hubs Integrating Cell Metabolism and Host Defense. Science (2020) 370(6514):1–12. doi: 10.1126/science.ayay085

Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL. Cholesterol and Fatty Acids Acquires a Dormancy-Like Phenotype in Lipid-Loaded Macrophages. Front Immunol (2021) 30(1):193–208. doi: 10.1111/imr.12962

Mattos KA, Oliveira VGC, Berrêdo-Pinheiro M, Amaral JJ, Antunes LCM, Melo RCM, et al. Mycobacterium Leprae Intracellular Survival Relies on Cholesterol Accumulation in Infected Macrophages: A Potential Target for New Drugs for Leprosy Treatment. Cell Microbiol (2014) 16(6):797–815. doi: 10.1111/cmi.12279

Kaur G, Kaur J. Multifaceted Role of Lipids in Mycobacterium Leprae. Future Microbiol (2017) 12(4):315–35. doi: 10.2217/fmb-2016-0173

Arvidges DS, Mellinger DL, Armstrong DA, Hazlett HF, Dessaint JA, Hampton TH, et al. Functional and Metabolic Impairment in Cigarette Smoke Exposed Macrophages. Pathog Dis (2018) 76(2):1–14. doi: 10.1093/infdis/fiy021

Neyrolles O, Wolschendorf F, Mitra A, Niederweis M. Mycobacteria, Metals, and the Macrophage. Immunol Rev (2015) 264(1):249–63. doi: 10.1111/imm.12265

Psu D, Huang L, Grenier JK, Russell DG. Dual RNA-Seq of Mtbc-Infected Macrophages in Vivo Reveals Ontologically Distinct Host-Pathogen Interactions. Cell Rep (2020) 30(2):335–350.e4. doi: 10.1016/j.celrep.2019.12.033

de Mattos Barbosa MG, da Silva Prata RB, Andrade PR, Ferreira H, de Andrade Silva BJ, da Paixão de Oliveira JA, et al. Indoleamine 2,3-Dioxygenase and Iron Are Required for Mycobacterium Leprae Survival. Microbes Infect (2017) 19(11):505–14. doi: 10.1016/j.micinf.2017.06.006

Karve TM, Cheema AK. Small Changes Have Huge Impact: The Role of Protein Posttranslational Modifications in Cellular Homeostasis and Disease. J Amino Acids (2011) 2011:1–13. doi: 10.4061/2011/207691

Liu J, Qian C, Cao X. Post-Translational Modification Control of Innate Immunity. Immun (2016) 45(1):13–30. doi: 10.1007/s41301-016-0020-0

Allis CD, Jenuwein T. The Molecular Hallmarks of Epigenetic Control. Nat Rev Genet (2016) 17(8):487–500. doi: 10.1038/nrg.2016.59

Zhang D, Tang Z, Huang H, Zhou G, Cui C, Weng Y, et al. Metabolic Regulation of Gene Expression by Histone Lactylation. Nature (2019) 574(7357):575–80. doi: 10.1038/s41586-019-1678-1

Dichtl S, Lindenthal L, Zeiter L, Behnke K, Schlosser D, Strobl B, et al. Lactate and IL6 Define Separable Paths of Inflammatory Metabolic Adaptation. Sci Adv (2021) 7(26):1–11. doi: 10.1126/sciadv.abg3505

Llibre A, Grudzinska FS, O’Shea MK, Duffy D, Thickett DR, Mauro C, et al. Lactate Crosstalk in Host-Pathogen Interactions. Biochim J (2021) 478(17):1357–78. doi: 10.1016/j.bcj.2021.02.063

Netea MG, Dominguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, et al. Defining Trained Immunity and Its Role in Health and Disease. Nat Rev Immunol (2020) 20(6):375–88. doi: 10.1038/s41577-020-0285-6

Chao WC, Yen CL, Wu YH, Chen SY, Hsieh CY, Chang TC, et al. Increased Resistin may Suppress Reactive Oxygen Species Production and Inflammammasome Activation in Type 2 Diabetic Patients With Pulmonary Tuberculosis Infection. Microbes Infect (2015) 17(3):193–204. doi: 10.1016/j.micinf.2014.11.009

Arts RJW, Carvalho A, La Rocca C, Palma C, Rodrigues F, Silvestre R, et al. Inflammammetabolitc Pathways in BCG-Induced Trained Immunity. Cell Rep (2016) 17(10):2562–71. doi: 10.1016/j.celrep.2016.11.013

Khan N, Downey J, Sanj I, Kaufmann H, Blankenhaus B, Pacis A, et al. M. Tuberculosis Reprogrooms Hematopoietic Stem Cells to Limit Myelopoiesis and Impair Trained Immunity. Cell (2020) 183(3):752–770.e22. doi: 10.1016/j.cell.2020.09.062

Batzer MA, Deininger PL. Alu Repeats and Human Genomic Diversity. Nat Rev Genet (2002) 3(5):370–9. doi: 10.1038/nrg7998

Bouttier M, Laperriere D, Memari B, Mangiapane J, Fiore A, Mitchell E, et al. Alu Repeats as Transcriptional Regulatory Platforms in Macrophage Metabolism and Host Defense. Nucleic Acids Res (2016) 44(22):10571–87. doi: 10.1093/nar/gkw782

Maruthi K, Subramanian M. Methylation Status of Alu Repetitive Elements in Children With Tuberculosis Disease. Int J Mycobacteriol (2017) 6(3):239–45. doi: 10.1016/j.ijmyco.2017.03.007

Holt PG, Keast D. Environmentally Induced Changes in Immunological Function: Acute and Chronic Effects of Inhalation of Tobacco Smoke and Other Atmospheric Contaminants in Man and Experimental Animals. Bacteriol Rev (1977) 41(1):205–16. doi: 10.1128/BR.41.1.205-1977

Holt PG. Immunological and Inflammatory Function in Cigarette Smokers. Thorax (1987) 42(4):224–9. doi: 10.1136/thorax.42.4.224

Sopori M. Effects of Cigarette Smoke on the Immune System. Nat Rev Immunol (2002) 2:337–72. doi: 10.1038/nri803

Stämpfli MR, Anderson GP. How Cigarette Smoke Skews Immune Responses to Promote Infection, Lung Disease and Cancer. Nat Rev Immunol (2009) 9(5):377–84. doi: 10.1038/nri2530

Qui F, Liang CI, Liu H, Zeng YQ, Hou S, Huang S, et al. Impacts of Cigarette Smoking on Immune Responsiveness: Up and Down or Upside Down? Oncotarget (2017) 8(1):268–84. doi: 10.18632/oncotarget.13613

O’Leary SM, Coleman MM, Chew WM, Morrow C, McLaughlin AM, Leary SM, et al. Does Smoking Impair Human Pulmonary Immunity to Mycobacterium Tuberculosis. Am J Respir Crit Care Med (2009) 179(8):784–93. doi: 10.1164/rccm.200808-118OC

Riedler J, Czernichow P, Fiehn O, Dettmer S, Schymik G, Klawitter J, et al. Tobacco Smoke Inhibits the NLRP3 Inflammasome and Leads to Caspase-1 Activation via the TLR4-TRIF-Caspase-8 Axis in Human Macrophages. Oncotarget (2017) 8(1):268–84. doi: 10.18632/oncotarget.13613

Boschetta M, Di Vincenzo S, Miele M, Badami E, Pace F, Cipollina C. Cigarette Smoke Inhibits the NLRP3 Inflammasome and Leads to Caspase-1 Activation via the TLR4-TRIF-Caspase-8 Axis in Human Macrophages. FASEB J (2020) 34(1):1819–32. doi: 10.1096/fj.20191239R

Stevenson CR, Crichtle JS, Forrest NG, Roglce G, Williams BG, Dye C, et al. Diabetes and the Risk of Tuberculosis: A Neglected Threat to Public Health? Chronic Illn (2007) 3(3):228–45. doi: 10.1177/1742395307081502
121. Dooley KE, Chaisson RE. Tuberculosis and Diabetes Mellitus: Convergence of Two Epidemics. *Lancet Infect Dis* (2009) 9(12):737–46. doi: 10.1016/S1473-3099(09)70282-8.

122. Linnroth K, Roglic G, Harries AD. Improving Tuberculosis Preven-Tion and Care Through Addressing the Global Diabetes Epidemic: From Evidence to Policy and Practice. *Lancet Diabetes Endocrinol* (2014) 2(9):730–9. doi: 10.1016/S2213-8587(14)70109-3.

123. Workneh MH, Bjune GA, Yimer SA. Prevalence and Associated Factors of Tuberculosis and Diabetes Mellitus Comorbidity: A Systematic Review. *PloS One* (2017) 12(4):1–25. doi: 10.1371/journal.pone.0175925.

124. Saiki O, Negoro S, Tsuyuguchi I, Yamamura Y. Depressed Immunological Defense Mechanisms in Mice With Experimentally Induced Diabetes. *Infect Immun* (1980) 28(1):127–31. doi: 10.1128/iai.28.1.127-131.1980.

125. Yamashiro S, Kawakami K, Uezu K, Kinjo T, Miyagi K, Nakamura K, et al. Lower Expression of Th1-Related Cytokines and Inducible Nitric Oxide Synthase in Mice With Streptozotocin-Induced Diabetes Mellitus Infected With Mycobacterium Tuberculosis. *Clin Exp Immunol* (2005) 139(1):57–64. doi: 10.1111/j.1365-2249.2005.02677.x.

126. Martens GW, Arikane MC, Lee J, Ren F, Greiner D, Kornfeld H. Tuberculosis Susceptibility of Diabetic Mice. *Am J Respir Cell Mol Biol* (2007) 37(5):518–24. doi: 10.1165/rcmb.2006-04780C.

127. Sugawara I, Mizuno S. Higher Susceptibility of Type 1 Diabetic Rats to Mycobacterium Tuberculosis Infection. *Tohoku J Exp Med* (2008) 216(2):163–70. doi: 10.1620/tjem.216.163.

128. Sugawara I, Yamada H, Mizuno S. Pulmonary Tuberculosis in Spontaneously Diabetic Goto-Kakizaki Rats. *Tohoku J Exp Med* (2004) 204(2):135–45. doi: 10.1620/tjem.204.135.

129. Podell BK, Ackart DF, Kirk NM, Eck SP, Bell C, Basaraba RJ. Non-Diabetic Susceptibility of Diabetic Mice. *Diabetes* (1999) 79(4):235–42. doi: 10.2337/diab.49.4.235.

130. Gomez DI, Twahirwa M, Schlesinger LS, Restrepo BI. Reduced Growth of M. Tuberculosis is More Associated With High Glucose Levels Than With Impaired Responses of Monocytes From T2D Patients. *J Infect Dis* (2019) 1–10. doi: 10.1155/2019/1462098.

131. Stew SS, Martinez PJ, Schlesinger LS, Restrepo BI. Differential Expression of Mycolate in Mice With Streptozotocin-Induced Diabetes Mellitus Infected With Mycobacterium Tuberculosis. *Clin Exp Immunol* (2005) 139(1):57–64. doi: 10.1111/j.1365-2249.2005.02677.x.

132. Lombardo N, Miele C, Locatelli V,和其他人.

133. Lachmandas E, Van Den Heuvel CNAM, Damen MSMA, Cleophas MCP,其他人.

134. Llibre et al. Host Adaptations to Mycobacterial Infection.
the CNS. Am J Physiol - Cell Physiol (2006) 291(4):618–26. doi: 10.1152/ajpcell.00021.2006

157. Ho PG, P. Prevedel L, Valdebenito S, Eugenin EA. HIV Infection and Latency Induce a Unique Metabolic Signature in Human Macrophages. Sci Rep (2019) 9(1):1–14. doi: 10.1038/s41598-019-39898-5

158. Hollenbaugh JA, Munger J, Kim B. Metabolite Profiles of Human Immunodeficiency Virus Infected CD4+ T Cells and Macrophages Using LC-MS/MS Analysis. Virology (2011) 415(2):153–9. doi: 10.1016/j.virol.2011.04.007

159. Bowman ER, Cameron CM, Richardson B, Kulkarni M, Gabriel J, Cichon MJ, et al. Macrophage Maturation From Blood Monocytes is Altered in People With HIV, and is Linked to Serum Lipid Profiles and Activation Indices: A Model for Studying Atherogenic Mechanisms. PloS Pathog (2020) 16(10):1–24. doi: 10.1371/journal.ppat.1008989

160. Bryson BD, Rosebrock TR, Tafesse FG, Itoh CY, Nibasumba A, Babunovic M, et al. Epidemiological and Clinical Patterns of 92 Patients Co-Infected With HIV and Tuberculosis: A Longitudinal Study From Rwanda. Front Cell Infect Microbiol (2019) 9(1):1–10. doi: 10.3389/fcimb.2018.00158

161. Naicker N, Sigal A, Naidoo K. Metformin as Host-Directed Therapy for TB Treatment: Scoping Review. Front Microbiol (2020) 11:1–11. doi: 10.3389/fmicb.2020.00435

162. Magee MJ, Salindri AD, Kornfeld H, Singhal A. Reduced Prevalence of Latent Tuberculosis Infection in Diabetes Patients Using Metformin and Statins. J Hematol Oncol (2018) 23(11):1063–73. doi: 10.1111/jho.13338

163. Singhal A, Jie L, Kumar P, Hong GS, Leow MKS, Paleja B, et al. Metformin as Adjunct Antituberculosis Therapy. Sci Transl Med (2014) 6(263):1–10. doi: 10.1126/scitranslmed.3009885

164. Pan SW, Yen YF, Kou YR, Chuang PH, Su VYF, Fung JY, et al. The Role of TB in Patients With Type 2 Diabetes Inhibiting Metformin vs Sulfonylurea Treatment. Chest (2018) 153(6):1347–57. doi: 10.1016/j.chest.2017.11.040

165. Lin SY, Tu HP, Lu PL, Chen TC, Wang WH, Chong IW, et al. Metformin is Associated With a Lower Risk of Active Tuberculosis in Patients With Type 2 Diabetes. Respir Physiol. (2018) 23(11):1063–73. doi: 10.1111/jres.13338

166. Degner NR, Wang YJ, Golub JE, Karakousis PC. Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment. Clin Infect Dis (2018) 66(2):198–205. doi: 10.1093/cid/cix819

167. Lee YJ, Han SK, Park JH, Lee JK, Kim DK, Chung HS, et al. The Effect of Metformin on Culture Conversion in Tuberculosis Patients With Diabetes Mellitus. Korean J Intern Med (2018) 33(5):933–40. doi: 10.3904/kjim.2017.249

168. Labuzek K, Liber S, Gabryel B, Adamczyk J, Okopien J. Phagocytosis of Mycobacterium Tuberculosis by Respiratory Epithelial Cells in Inflammation Models. Front Cell Infect Microbiol (2020) 11:1–8. doi: 10.3389/fcimb.2019.00158

169. Moreno JR, García IE, de la Luz García Hernández M, Leon DA, Marquez R, Pando RH. The Role of Prostaglandin E2 in the Immunopathogenesis of Experimental Pulmonary Tuberculosis. Immunology (2002) 106(2):257–66. doi: 10.1046/j.1365-2567.2002.01403.x

170. Duan H, Liu T, Zhang X, Yu A, Cao Y. Statin Use and Risk of Tuberculosis: A Systematic Review of Observational Studies. Int J Infect Dis (2020) 93:168–74. doi: 10.1016/j.ijid.2020.01.036

171. Hennessy E, Adams C, Reen FJ, O’Gara F. Is There Potential for Repurposing Statins as Novel Antimicrobials? Antimicrob Agents Chemother (2016) 60(9):5111–21. doi: 10.1128/AAC.00192-16
194. Dutta NK, Bruiners MS, De Leon A, Pellegrini M, Krutzik SR, et al. All-Trans Retinoic Acid Augments Autophagy During Intracellular Bacterial Infection. Am J Respir Cell Mol Biol (2018) 59(5):548–56. doi: 10.1165/ajrccm.2017-0382OC.

195. Wheelwright M, Kim EW, Inkeles MS, De Leon A, Pellegrini M, Krutzik SR, et al. High-Dose Vitamin D3 During Intensive-Phase Antimicrobial Treatment of Pulmonary Tuberculosis: A Double-Blind Randomised Controlled Trial. Lancet (2011) 377(9761):242–50. doi: 10.1016/S0140-6736(10)61889-2.

196. Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Elkington PT, et al. The Role of Glutamine Metabolism in Host Defense Against Mycobacterium Tuberculosis Infection. J Infect Dis (2019) 219(10):1662–70. doi: 10.1093/infdis/jiy709.

197. Rapowy SM, Zhao J, Bricker RL, Schmidt SM, Setchell KDR, Qualls JE. Differential Requirements for L-Citrulline and L-Arginine During Antimycobacterial Macrophage Activity. J Immunol (2015) 195(7):3293–300. doi: 10.4049/jimmunol.1500860.

198. Li X, Kazmi KC, Pesci JT, Smith AM, Thompson RW, Henao-Tamayo M, et al. Toll-Like Receptor-Induced Arginase 1 in Macrophages Thwarts Effective Immunity Against Intracellular Pathogens. Nat Immunol (2008) 9(12):399–406. doi: 10.1038/ni.1671.

199. Lange SM, McKeel MC, Schmidt SM, Zhao J, Crowther RR, Green LC, et al. L-Arginine Synthesis From L-Citrulline in Myeloid Cells Drives Host Defense Against Mycobacteria In Vivo. J Immunol (2019) 202(6):1747–54. doi: 10.4049/jimmunol.1801569.

200. Mattila JT, Ojo OO, Kepta-Lehanti D, Marino S, Kim JH, Eum SY, et al. Microenvironments in Tuberculous Granulomas are Delineated by Distinct Populations of Macrophage Subsets and Expression of Nitric Oxide Synthase and Arginase Isomers. J Immunol (2013) 191(2):773–84. doi: 10.4049/jimmunol.1300113.

201. Zhang YJ, Reddy MC, loerger TR, Rothchild DC, Darois V, Schuster BM, et al. Tryptophan Biosynthesis Protects Mycobacteria From CD4 T-Cell-Mediated Killing. Cell (2013) 155(6):1296–308. doi: 10.1016/j.cell.2013.10.045.

202. Abate Negatu D, Yamada Y, Xi Y, Lin Go M, Zimmerman M, Ganapathy U, et al. Gut Microbiota Metabolite Indole Propionic Acid Targets Tryptophan Biosynthesis in Mycobacterium Tuberculosis. MBio (2019) 10(2):1–15. doi: 10.1128/mBio.02781-18.

203. Blumenthal A, Nagalingam G, Huch JH, Walker L, Guillemin GL, Smythe GA, et al. M. Tuberculosis Induces Potent Activation of Ido-1, But This is Not Essential for the Immunological Control of Infection. PloS One (2012) 7(5):1–11. doi: 10.1371/journal.pone.0037314.

204. Dutta NK, Bruiners MS, Conerly CN, Philipp-Falkenstein K, Alvarez X, et al. Transcriptional Reprogramming in Nonhuman Primate (Rhesus Macaque) Tuberculosis Granulomas. PloS One (2010) 5(8):1–12. doi: 10.1371/journal.pone.0012266.

205. Moura-Alves P, Fae K, Houthuys E, Dorhao I, Kreuchwig A, Furkert J, et al. Ahr Sensing of Bacterial Pigments Regulates Antibacterial Defence. Nature (2014) 512(7515):387–92. doi: 10.1038/nature13684.

206. Kim JS, Kim YR, Yang CS. Host-Directed Therapy in Tuberculosis: Targeting Host Metabolism. Front Immunol (2020) 11:1–12. doi: 10.3389/fimmu.2020.01790.

207. Park JH, Shin D, Kim KES, Lee W, Shin SJ. Understanding Metabolic Regulation Between Host and Pathogens: New Opportunities for the Development of Improved Therapeutic Strategies Against Mycobacterium Tuberculosis Infection. Front Cell Infect Microbiol (2021) 11:1–21. doi: 10.3389/fcimb.2021.63535.

208. Crowther RR, Qualls JE. Metabolic Regulation of Immune Responses to Mycobacterium Tuberculosis: A Spotlight on L-Arginine and L-Tryptophan Metabolism. Front Immunol (2021) 11:1–16. doi: 10.3389/fimmu.2020.628432.

209. Kiran D, Basaraba RJ. Lactate Metabolism and Signaling in Tuberculosis and Cancer: A Comparative Review. Front Cell Infect Microbiol (2021) 11:2–14. doi: 10.3389/fcimb.2021.624607.

210. Lobato LS, Rosa PS, Da Silva Ferreira J, Da Silva Neumann A, Da Silva MG, Nascimento DC, et al. Statins Increase Rifampin Mycobactericidal Effect. Antimicrob Agents Chemother (2014) 58(10):5766–74. doi: 10.1128/AAC.01826-13.

211. Castillo EF, Dekonzeno A, Arko-Mensah J, Mandell MA, Dupont N, Jiang S, et al. Autophagy Protegrs Against Active Tuberculosis by Suppressing Bacterial Burden and Inflammation. Proc Natl Acad Sci USA (2012) 109(46):1–9. doi: 10.1073/pnas.1210500109.

212. Saini NK, Baena A, Ng TW, Venkataswamy MM, Kennedy SC, Kunnath-VELayudhan S, et al. Suppression of Autophagy and Antigen Presentation by Mycobacterium Tuberculosis PE-PGRS47. Nat Microbiol (2016) 1(5):1–12. doi: 10.1038/nmicrobiol.2016.133.

213. Evans MI, Levy L. Ultrastructural Changes in Cells of the Mice Footpad Infected With Mycobacterium Leprae. Infect Immun (1972) 5(2):238–47. doi: 10.1128/iai.5.2.238-247.1972.

214. Silva BJ de A, Barbosa MG de M, Andrade PR, Ferreira H, Sarto JA de C, Corté-Real S, et al. Autophagy is an Innate Mechanism Associated With Leprosy Polarization. PloS Pathog (2017) 13(1):1–29. doi: 10.1371/journal.ppat.1006103.

215. Sideg PA, Modlin RL. Cytokine Patterns at the Site of Mycobacterial Infection. Immunobiology (1994) 4–5:378–87. doi: 10.1016/S0171-2985(11)80443-2.

216. Dang AT, Teles RMB, Weiss DI, Parvativiy K, Sarno EN, Hochoh MT, et al. IL-26 Contributes to Host Defense Against Intracellular Bacteria. J Clin Invest (2019) 129(5):1926–39. doi: 10.1172/JCI99550.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim of manufacture, is that of the manufacturer, or is not guaranteed or endorsed by the publisher.

Copyright © 2021 Libbre, Dedicoat, Barel, Demangel, O’Shea and Mauro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.